Manila Times Business
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p - This is the first and only Phase 3 data for an achondroplasia clinical study published in The New England Journal of Medicine (NEJM), marking BridgeBio’s second NEJM publication in achondroplasia and fourth NEJM publication overall in the la
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Mid-Year Comfort Upgrade Season: A Better Way to Support Everyday Life with Oxygen Concentrators
2h ago
Fibocom and Digital Matter Accelerate Asset Tracking Deployments Across Global Markets
2h ago
Greenhouse and hipages Group Win the 2026 TIARA Long-Term Partnership Award
2h ago
If AI Is Such a Sure Thing, Why Are So Many Insiders Selling?
3h ago